SynthesisFrontiers in immunology2026
Radiotherapy plus immune checkpoint inhibitors versus immune checkpoint inhibitors alone for non-small cell lung cancer with bone metastases: a systematic review and meta-analysis of comparative cohort studies.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bone metastases are a frequent and clinically consequential complication of advanced non-small cell lung cancer (NSCLC), associated with substantial morbidity and poor survival. Whether adding radiotherapy (RT) to immune checkpoint inhibitors (ICIs) improves outcomes remains uncertain. Methods: We searched PubMed, Cochrane Library, Web of Science, Scopus, and Embase (January 2010-October 2025) for comparative studies of RT + ICI versus ICI alone in patients with NSCLC and radiologically or pathologically confirmed bone metastases. Primary outcomes were overall survival (OS) and progression-free survival (PFS); secondary outcomes were objective response rate (ORR), grade ≥3 adverse events (AEs), and skeletal-related events (SREs). Study quality was assessed using the Newcastle-Ottawa Scale. Hazard ratios (HRs) were pooled for time-to-event outcomes and odds ratios (ORs) for binary outcomes, using fixed- or random-effects models according to heterogeneity. Results: Six studies (n = 1,631) were included. RT + ICI improved OS (HR 0.58, 95% CI 0.44-0.76; I² = 68%) and PFS (HR 0.44, 95% CI 0.37-0.53; I² = 0%) versus ICI alone. The OS benefit persisted after excluding the large database cohort (HR 0.52, 95% CI 0.42-0.63). ORR was not significantly different (OR 1.68, 95% CI 0.77-3.66; I² = 74%), and grade ≥3 AEs were comparable (OR 1.00, 95% CI 0.78-1.27; I² = 0%). RT + ICI reduced SREs (OR 0.16, 95% CI 0.04-0.68; I² = 0%), but this estimate is based on sparse events. Conclusions: Low- to moderate-quality observational evidence suggests that RT combined with ICIs may be associated with improved survival without an apparent increase in severe toxicity in NSCLC with bone metastases. Any apparent reduction in SREs should be interpreted cautiously given the sparse event data. Prospective phase III randomized trials are needed to confirm causality and refine patient selection. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251230736.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.